Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research report released on Tuesday, Benzinga reports. The firm currently has a $50.00 target price on the biotechnology company’s stock.

A number of other research analysts have also weighed in on the stock. Stephens initiated coverage on shares of Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They set an overweight rating and a $25.00 target price for the company. Cantor Fitzgerald reaffirmed an overweight rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. StockNews.com raised shares of Actinium Pharmaceuticals from a sell rating to a hold rating in a research report on Sunday, May 5th. Finally, Maxim Group upped their price objective on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a buy rating in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Actinium Pharmaceuticals presently has an average rating of Moderate Buy and an average target price of $25.60.

Actinium Pharmaceuticals Price Performance

Shares of NYSEAMERICAN:ATNM opened at $8.50 on Tuesday. The firm has a market capitalization of $253.13 million, a P/E ratio of -4.97 and a beta of 0.08. Actinium Pharmaceuticals has a 1 year low of $4.00 and a 1 year high of $10.24.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. As a group, equities analysts anticipate that Actinium Pharmaceuticals will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds have recently bought and sold shares of ATNM. Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals in the 3rd quarter valued at $1,033,000. Creative Financial Designs Inc. ADV grew its position in shares of Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 3,175 shares during the period. Vanguard Group Inc. grew its position in shares of Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares during the period. Virtu Financial LLC grew its position in shares of Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock valued at $642,000 after acquiring an additional 62,459 shares during the period. Finally, Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals in the 1st quarter valued at about $78,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.